Conference/Events
|
Healthcare Analysts,… Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link ShowHide Related Items >><< TPTX Turning Point Therapeutics - 10/13/21
- Turning Point, EQRx team to evaluate elzovantinib/aumolertinib combo in NSCLC
- 10/08/21
- Turning Point Therapeutics presents TRIDENT-1 clinical data for repotrectinib
- 10/07/21
- Turning Point Therapeutics provides regulatory update
- 10/07/21
- Turning Point presents updated preliminary clinical data for elzovantinib
RVMD Revolution Medicines - 06/24/21
- Revolution Medicines publishes data on mTORC1-selective inhibitors
- 06/10/21
- Revolution Medicines to host webcast on studies of RAS inhibitors
- 05/03/21
- Revolution Medicines highlights board of directors nominees for upcoming meeting
- 04/30/21
- Revolution Medicines does not expect RMC-4630, sotorasib data in 2021
- 10/14/21
- Genentech announces new Espryng efficacy, safety data at ECTRIMS
- 10/13/21
- Roche says new long-term data reinforce benefit of ocrelizumab in relapsing MS
- 10/11/21
- Sarepta announces functional data from SRP-9001 development program
- 10/08/21
- Roche's gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's
- 10/11/21
- Novartis' Sandoz completes acquisition of GSK's cephalosporin business
- 10/06/21
- Rafael names Mary Margaret Huizinga as chief development and medical officer
- 10/01/21
- Sandoz resolves legacy U.S. federal government civil investigation
- 10/01/21
- Three generic drug makers to pay $447.2M to settle price-fixing claims, DOJ says
- 10/07/21
- Mirati, Sanofi to collaborate on adagrasib-SHP2 Inhibitor combo
- 09/20/21
- Mirati Therapeutics announces results from Phase 2 study of MRTX-500
- 09/20/21
- Mirati Therapeutics appoints David Meek as Chief Executive Officer
- 09/20/21
- Mirati Therapeutics announce Phase 2 topline results for adagrasib
- 06/14/21
- G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela
- 10/08/21
- AstraZeneca announces Tezepelumab granted orphan drug designation
- 10/07/21
- Amgen reports Phase 1b data from Lumakras combination in cancer
- 10/07/21
- Amgen, Neumora enter collaboration to advance neuroscience discovery
- 10/04/21
- BioMarin hires Bernstein as CMO, Vedantham as senior VP
TPTX Turning Point Therapeutics - 10/12/21 H.C. Wainwright
- Turning Point price target lowered to $162 from $178 at H.C. Wainwright
- 10/11/21 JMP Securities
- Turning Point downgraded to Market Perform from Outperform at JMP Securities
- 10/08/21 Roth Capital
- Turning Point selloff brings 'bargain value,' says Roth Capital
- 10/08/21 Wedbush
- Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush
- 10/13/21 Morgan Stanley
- Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
- 09/20/21 Citi
- Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
- 09/09/21 RBC Capital
- Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
- 09/07/21 UBS
- Roche price target raised to CHF 350 from CHF 345 at UBS
- 10/12/21 Berenberg
- Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
- 10/08/21 UBS
- Novartis price target lowered to CHF 92 from CHF 95 at UBS
- 09/29/21 Stifel
- Blueprint Medicines rersumed with a Hold at Stifel
- 09/20/21 Deutsche Bank
- Novartis downgraded to Sell from Hold at Deutsche Bank
- 09/17/21 Morgan Stanley
- Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
- 09/13/21 Deutsche Bank
- Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
- 09/10/21 JPMorgan
- Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
- 09/02/21 Barclays
- Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
- 09/22/21 Stifel
- Mirati Therapeutics initiated with a Buy at Stifel
- 09/22/21 Citi
- Mirati Therapeutics price target raised to $244 from $232 at Citi
- 09/21/21 Oppenheimer
- Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer
- 09/07/21 JPMorgan
- Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan
- 10/04/21 Piper Sandler
- Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
- 09/23/21 Daiwa
- Amgen downgraded to Neutral from Outperform at Daiwa
RVMD Revolution Medicines - 09/22/21 Stifel
- Revolution Medicines initiated with a Hold at Stifel
- 08/17/21 H.C. Wainwright
- Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
- 08/12/21
- Fly Intel: Top five analyst downgrades
- 08/12/21 Guggenheim
- Revolution Medicines price target lowered to $34 from $52 at Guggenheim
TPTX Turning Point Therapeutics - 08/09/21
- Turning Point Therapeutics reports Q2 EPS (1.14c), consensus ($1.21)
RVMD Revolution Medicines - 08/11/21
- Revolution Medicines reports Q2 EPS (60c), consensus (48c)
- 05/10/21
- Revolution Medicines reports Q1 EPS (53c), consensus (52c)
- 07/22/21
- Roche reports 1H21 core EPS CHF10.56 vs. CHF10.44 last year
- 04/21/21
- Roche reports Q1 group sales CHF 14.93B vs. CHF 15.14B last year
- 07/21/21
- Novartis continues to expect FY21 core operating income to grow mid single digit
- 07/21/21
- Novartis reports Q2 core EPS $1.66, consensus $1.52
- 04/27/21
- Novartis sees FY21 core operating income to grow mid single digit percentage
- 04/27/21
- Novartis reports Q1 core EPS $1.52, consensus $1.59
- 08/05/21
- Mirati Therapeutics reports Q2 EPS ($3.23), consensus ($2.40)
- 05/06/21
- Mirati Therapeutics reports Q1 EPS ($2.67), consensus ($2.13)
- 08/03/21
- Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.34
- 08/03/21
- Amgen reports Q2 adjusted EPS $4.38, consensus $4.06
- 08/03/21
- Notable companies reporting after market close
- 04/27/21
- Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.80
|
Conference/Events
|
Healthcare Analysts,… Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link ShowHide Related Items >><< TPTX Turning Point Therapeutics - 10/13/21
- Turning Point, EQRx team to evaluate elzovantinib/aumolertinib combo in NSCLC
- 10/08/21
- Turning Point Therapeutics presents TRIDENT-1 clinical data for repotrectinib
- 10/07/21
- Turning Point Therapeutics provides regulatory update
- 10/07/21
- Turning Point presents updated preliminary clinical data for elzovantinib
RVMD Revolution Medicines - 06/24/21
- Revolution Medicines publishes data on mTORC1-selective inhibitors
- 06/10/21
- Revolution Medicines to host webcast on studies of RAS inhibitors
- 05/03/21
- Revolution Medicines highlights board of directors nominees for upcoming meeting
- 04/30/21
- Revolution Medicines does not expect RMC-4630, sotorasib data in 2021
- 10/13/21
- Roche says new long-term data reinforce benefit of ocrelizumab in relapsing MS
- 10/11/21
- Sarepta announces functional data from SRP-9001 development program
- 10/08/21
- Roche's gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's
- 10/05/21
- Genentech to present new Ocrevus, Enspryng data at ECTRIMS
- 10/11/21
- Novartis' Sandoz completes acquisition of GSK's cephalosporin business
- 10/06/21
- Rafael names Mary Margaret Huizinga as chief development and medical officer
- 10/01/21
- Sandoz resolves legacy U.S. federal government civil investigation
- 10/01/21
- Three generic drug makers to pay $447.2M to settle price-fixing claims, DOJ says
- 10/07/21
- Mirati, Sanofi to collaborate on adagrasib-SHP2 Inhibitor combo
- 09/20/21
- Mirati Therapeutics announces results from Phase 2 study of MRTX-500
- 09/20/21
- Mirati Therapeutics appoints David Meek as Chief Executive Officer
- 09/20/21
- Mirati Therapeutics announce Phase 2 topline results for adagrasib
- 06/14/21
- G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela
- 10/08/21
- AstraZeneca announces Tezepelumab granted orphan drug designation
- 10/07/21
- Amgen reports Phase 1b data from Lumakras combination in cancer
- 10/07/21
- Amgen, Neumora enter collaboration to advance neuroscience discovery
- 10/04/21
- BioMarin hires Bernstein as CMO, Vedantham as senior VP
TPTX Turning Point Therapeutics - 10/12/21 H.C. Wainwright
- Turning Point price target lowered to $162 from $178 at H.C. Wainwright
- 10/11/21 JMP Securities
- Turning Point downgraded to Market Perform from Outperform at JMP Securities
- 10/08/21 Roth Capital
- Turning Point selloff brings 'bargain value,' says Roth Capital
- 10/08/21 Wedbush
- Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush
- 10/13/21 Morgan Stanley
- Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
- 09/20/21 Citi
- Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
- 09/09/21 RBC Capital
- Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
- 09/07/21 UBS
- Roche price target raised to CHF 350 from CHF 345 at UBS
- 10/12/21 Berenberg
- Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
- 10/08/21 UBS
- Novartis price target lowered to CHF 92 from CHF 95 at UBS
- 09/29/21 Stifel
- Blueprint Medicines rersumed with a Hold at Stifel
- 09/20/21 Deutsche Bank
- Novartis downgraded to Sell from Hold at Deutsche Bank
- 09/17/21 Morgan Stanley
- Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
- 09/13/21 Deutsche Bank
- Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
- 09/10/21 JPMorgan
- Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
- 09/02/21 Barclays
- Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
- 09/22/21 Stifel
- Mirati Therapeutics initiated with a Buy at Stifel
- 09/22/21 Citi
- Mirati Therapeutics price target raised to $244 from $232 at Citi
- 09/21/21 Oppenheimer
- Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer
- 09/07/21 JPMorgan
- Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan
- 10/04/21 Piper Sandler
- Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
- 09/23/21 Daiwa
- Amgen downgraded to Neutral from Outperform at Daiwa
RVMD Revolution Medicines - 09/22/21 Stifel
- Revolution Medicines initiated with a Hold at Stifel
- 08/17/21 H.C. Wainwright
- Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
- 08/12/21
- Fly Intel: Top five analyst downgrades
- 08/12/21 Guggenheim
- Revolution Medicines price target lowered to $34 from $52 at Guggenheim
TPTX Turning Point Therapeutics - 08/09/21
- Turning Point Therapeutics reports Q2 EPS (1.14c), consensus ($1.21)
RVMD Revolution Medicines - 08/11/21
- Revolution Medicines reports Q2 EPS (60c), consensus (48c)
- 05/10/21
- Revolution Medicines reports Q1 EPS (53c), consensus (52c)
- 07/22/21
- Roche reports 1H21 core EPS CHF10.56 vs. CHF10.44 last year
- 04/21/21
- Roche reports Q1 group sales CHF 14.93B vs. CHF 15.14B last year
- 07/21/21
- Novartis continues to expect FY21 core operating income to grow mid single digit
- 07/21/21
- Novartis reports Q2 core EPS $1.66, consensus $1.52
- 04/27/21
- Novartis sees FY21 core operating income to grow mid single digit percentage
- 04/27/21
- Novartis reports Q1 core EPS $1.52, consensus $1.59
- 08/05/21
- Mirati Therapeutics reports Q2 EPS ($3.23), consensus ($2.40)
- 05/06/21
- Mirati Therapeutics reports Q1 EPS ($2.67), consensus ($2.13)
- 08/03/21
- Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.34
- 08/03/21
- Amgen reports Q2 adjusted EPS $4.38, consensus $4.06
- 08/03/21
- Notable companies reporting after market close
- 04/27/21
- Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.80
|
Conference/Events
|
Healthcare Analysts,… Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link ShowHide Related Items >><< TPTX Turning Point Therapeutics - 10/08/21
- Turning Point Therapeutics presents TRIDENT-1 clinical data for repotrectinib
- 10/07/21
- Turning Point Therapeutics provides regulatory update
- 10/07/21
- Turning Point presents updated preliminary clinical data for elzovantinib
- 10/07/21
- Turning Point presents updated preliminary clinical data for repotrectinib
RVMD Revolution Medicines - 06/24/21
- Revolution Medicines publishes data on mTORC1-selective inhibitors
- 06/10/21
- Revolution Medicines to host webcast on studies of RAS inhibitors
- 05/03/21
- Revolution Medicines highlights board of directors nominees for upcoming meeting
- 04/30/21
- Revolution Medicines does not expect RMC-4630, sotorasib data in 2021
- 10/11/21
- Sarepta announces functional data from SRP-9001 development program
- 10/08/21
- Roche's gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's
- 10/05/21
- Genentech to present new Ocrevus, Enspryng data at ECTRIMS
- 10/04/21
- Sarepta announces initiation of EMBARK study of SRP-9001
- 10/11/21
- Novartis' Sandoz completes acquisition of GSK's cephalosporin business
- 10/06/21
- Rafael names Mary Margaret Huizinga as chief development and medical officer
- 10/01/21
- Sandoz resolves legacy U.S. federal government civil investigation
- 10/01/21
- Three generic drug makers to pay $447.2M to settle price-fixing claims, DOJ says
- $167.96 /
-0.275 (-0.16%) - 10/07/21
- Mirati, Sanofi to collaborate on adagrasib-SHP2 Inhibitor combo
- 09/20/21
- Mirati Therapeutics announces results from Phase 2 study of MRTX-500
- 09/20/21
- Mirati Therapeutics appoints David Meek as Chief Executive Officer
- 09/20/21
- Mirati Therapeutics announce Phase 2 topline results for adagrasib
- $43.18 /
-0.0125 (-0.03%) - 06/14/21
- G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela
- 10/08/21
- AstraZeneca announces Tezepelumab granted orphan drug designation
- 10/07/21
- Amgen reports Phase 1b data from Lumakras combination in cancer
- 10/07/21
- Amgen, Neumora enter collaboration to advance neuroscience discovery
- 10/04/21
- BioMarin hires Bernstein as CMO, Vedantham as senior VP
TPTX Turning Point Therapeutics - 10/11/21 JMP Securities
- Turning Point downgraded to Market Perform from Outperform at JMP Securities
- 10/08/21 Roth Capital
- Turning Point selloff brings 'bargain value,' says Roth Capital
- 10/08/21 Wedbush
- Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush
- 10/07/21 Wells Fargo
- Turning Point Therapeutics price target lowered to $120 from $160 at Wells Fargo
- 09/20/21 Citi
- Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
- 09/09/21 RBC Capital
- Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
- 09/07/21 UBS
- Roche price target raised to CHF 350 from CHF 345 at UBS
- 08/02/21 JPMorgan
- Roche price target raised to CHF 360 from CHF 310 at JPMorgan
- 10/08/21 UBS
- Novartis price target lowered to CHF 92 from CHF 95 at UBS
- 09/29/21 Stifel
- Blueprint Medicines rersumed with a Hold at Stifel
- 09/20/21 Deutsche Bank
- Novartis downgraded to Sell from Hold at Deutsche Bank
- $43.18 /
-0.0125 (-0.03%) - 09/17/21 Morgan Stanley
- Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
- 09/13/21 Deutsche Bank
- Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
- 09/10/21 JPMorgan
- Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
- 09/02/21 Barclays
- Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
- $167.96 /
-0.275 (-0.16%) - 09/22/21 Stifel
- Mirati Therapeutics initiated with a Buy at Stifel
- 09/22/21 Citi
- Mirati Therapeutics price target raised to $244 from $232 at Citi
- 09/21/21 Oppenheimer
- Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer
- 09/07/21 JPMorgan
- Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan
- 10/04/21 Piper Sandler
- Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
- 09/23/21 Daiwa
- Amgen downgraded to Neutral from Outperform at Daiwa
RVMD Revolution Medicines - 09/22/21 Stifel
- Revolution Medicines initiated with a Hold at Stifel
- 08/17/21 H.C. Wainwright
- Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
- 08/12/21
- Fly Intel: Top five analyst downgrades
- 08/12/21 Guggenheim
- Revolution Medicines price target lowered to $34 from $52 at Guggenheim
TPTX Turning Point Therapeutics - 08/09/21
- Turning Point Therapeutics reports Q2 EPS (1.14c), consensus ($1.21)
RVMD Revolution Medicines - 08/11/21
- Revolution Medicines reports Q2 EPS (60c), consensus (48c)
- 05/10/21
- Revolution Medicines reports Q1 EPS (53c), consensus (52c)
- 07/22/21
- Roche reports 1H21 core EPS CHF10.56 vs. CHF10.44 last year
- 04/21/21
- Roche reports Q1 group sales CHF 14.93B vs. CHF 15.14B last year
- 07/21/21
- Novartis continues to expect FY21 core operating income to grow mid single digit
- 07/21/21
- Novartis reports Q2 core EPS $1.66, consensus $1.52
- 04/27/21
- Novartis sees FY21 core operating income to grow mid single digit percentage
- 04/27/21
- Novartis reports Q1 core EPS $1.52, consensus $1.59
- $167.96 /
-0.275 (-0.16%) - 08/05/21
- Mirati Therapeutics reports Q2 EPS ($3.23), consensus ($2.40)
- 05/06/21
- Mirati Therapeutics reports Q1 EPS ($2.67), consensus ($2.13)
- 08/03/21
- Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.34
- 08/03/21
- Amgen reports Q2 adjusted EPS $4.38, consensus $4.06
- 08/03/21
- Notable companies reporting after market close
- 04/27/21
- Amgen backs FY21 adjusted EPS view $16.00-$17.00, consensus $16.80
|
Recommendations
|
Morgan Stanley analyst… Morgan Stanley analyst Mark Purcell raised the firm's price target on Merck KGaA to EUR 200 from EUR 185 and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< - 06/14/21
- G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela
- 03/18/21
- Exelixis enters STELLAR-001 pact, supply agreement with Merck KGaA and Pfizer
- 09/13/21 Deutsche Bank
- Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
- 09/10/21 JPMorgan
- Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
- 09/02/21 Barclays
- Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
- 08/10/21 Morgan Stanley
- Merck KGaA price target raised to EUR 185 from EUR 145 at Morgan Stanley
|
Recommendations
|
Deutsche Bank analyst… Deutsche Bank analyst Falko Friedrichs raised the firm's price target on Merck KGaA to EUR 240 from EUR 220 and keeps a Buy rating on the shares. ShowHide Related Items >><< - 06/14/21
- G1 Therapeutics initiates PRESERVE 3, phase 2 study of cosela
- 03/18/21
- Exelixis enters STELLAR-001 pact, supply agreement with Merck KGaA and Pfizer
- 09/10/21 JPMorgan
- Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
- 09/02/21 Barclays
- Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
- 08/10/21 Morgan Stanley
- Merck KGaA price target raised to EUR 185 from EUR 145 at Morgan Stanley
- 08/09/21 Deutsche Bank
- Merck KGaA price target raised to EUR 220 from EUR 155 at Deutsche Bank
|